News

Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor

Erasca, a clinical-stage precision oncology company founded on UCSF professor Kevan Shokat's MedTech research, and focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States Food and Drug Administration has...

Vevo Therapeutics Launches with $12M Seed Financing

Mosaic drug discovery platform is the first to make in vivo data generation scalable, with single-cell precision; resulting datasets will be the world's largest atlas of how drugs interact with patient cells. This approach combines an atlas with AI models to capture in vivo context of disease early...

New Liquid Biopsy Detects Breast Cancer at Its Earliest Stages

Exai Bio and researchers at UCSF released data demonstrating that Exai’s novel, RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages and smallest tumor sizes. Earlier detection of breast cancer is crucial for optimal patient outcomes but cannot always be...

Rezo, Founded by Renowned UCSF Scientists, Launches with $78 Million

Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, launched today with $78 million from a Series A financing. The Series A financing was led by SR One, a16z Bio + Health, and Norwest Venture Partners, and also included SV...

How oncRNA Technology Could Revolutionize Cancer Diagnostics

An interview with Pat Arensdorf, co-founder and chief executive officer of Exai Bio, a biotech company founded on the scientific discoveries of UCSF's biochemistry professor Hani Goodarzi, PhD. MORE

MindRhythm Expands Beyond Strokes to Include Concussions

MindRhythm, a medical device technology company focused on preventing neurological injury, announces today the expansion of its exclusive worldwide stroke licensing agreement with the University of California San Francisco (UCSF) to include concussions.

FDA Grants Orphan Drug Designation for Vanda's Cholera Treatment

Vanda Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VPO-227, a drug discovered by UCSF researcher Alan Verkman, PhD, for the treatment of cholera. more

Erasca Collaborates with Pfizer

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced a clinical trial collaboration and supply agreement (CTCSA) with Pfizer Inc. for the CDK4/6 inhibitor...

Nested Therapeutics Launches With $125 Million Financing

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers that are founded on UCSF professor Kevan Shokat's technology, today announced the completion of a $90 million Series A financing led by the Life Sciences Investing...

Exai Bio Novel RNA-based Liquid Biopsy Platform May Detect Colorectal Cancer Early

Exai Bio, a next-generation liquid biopsy company, and researchers led by Professor Hani Goodarzi at UCSF are presenting data from a new study in a poster entitled "Serum-based colorectal cancer detection using orphan noncoding RNAs" at the 2022 European Society of Medical Oncology (ESMO) meeting.